The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2
Open accessAbstract
Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has been identified as the causal agent of COronaVIrus Disease‐19 (COVID‐19), an atypical pneumonia‐like syndrome that emerged in December 2019. While SARS‐CoV‐2 titers can be measured by detection of viral nucleic acid, this method is unable to quantitate infectious virions. Measurement of infectious SARS‐CoV‐2 can be achieved by tissue culture infectious dose−50 (TCID 50), which detects the presence or absence of cytopathic effect in cells infected with serial dilutions of a virus specimen. However, this method only provides a qualitative infectious virus titer. Plaque assays are a quantitative method of measuring infectious SARS‐CoV‐2 by quantifying the plaques formed in cell culture upon infection with serial dilutions of a virus specimen. As such, plaque assays remain the gold standard in quantifying concentrations of replication‐competent lytic virions. Here, we describe two detailed plaque assay protocols to quantify infectious SARS‐CoV‐2 using different overlay and staining methods. Both methods have several advantages and disadvantages, which can be considered when choosing the procedure best suited for each laboratory. These assays can be used for several research purposes, including titration of virus stocks produced from infected cell supernatant and, with further optimization, quantification of SARS‐CoV‐2 in specimens collected from infected animals. © 2019 The Authors. Basic Protocol: SARS‐CoV‐2 plaque assay using a solid double overlay method Alternate Protocol: SARS‐CoV‐2 plaque assay using a liquid overlay and fixation‐staining method
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004973 · Cited by 9,951
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,344
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Neutral red uptake assay for the estimation of cell viability/cytotoxicity
Repetto, G., del Peso, A., & Zurita, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.75 · Cited by 2,207
Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia
Chu, D. K. W., Pan, Y., Cheng, S. M. S., Hui, K. P. Y., Krishnan, P., Liu, Y., Ng, D. Y. M., Wan, C. K. C., Yang, P., Wang, Q., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa029 · Cited by 1,278
Crystal Violet Assay for Determining Viability of Cultured Cells
Feoktistova, M., Geserick, P., & Leverkus, M. (2016) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot087379 · Cited by 887
Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
Harcourt, J., Tamin, A., Lu, X., Kamili, S., Sakthivel, S. K., Murray, J., Queen, K., Tao, Y., Paden, C. R., Zhang, J., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2606.200516 · Cited by 542
Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems
Baer, A., & Kehn-Hall, K. (2014) · Journal of Visualized Experiments · doi:10.3791/52065 · Cited by 441
Management of Critically Ill Adults With COVID-19
Poston, J. T., Patel, B. K., & Davis, A. M. (2020) · JAMA · doi:10.1001/jama.2020.4914 · Cited by 367
Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α
Ströher, U., DiCaro, A., Li, Y., Strong, J. E., Aoki, F., Plummer, F., Jones, S. M., & Feldmann, H. (2004) · The Journal of Infectious Diseases · doi:10.1086/382597 · Cited by 210
The Plaque Assay of Animal Viruses
Cooper, P. D. (1962) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60689-2 · Cited by 193
Basic Techniques in Mammalian Cell Tissue Culture
Phelan, K., & May, K. M. (2015) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0101s66 · Cited by 162
Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems
Baer, A., & Kehn-Hall, K. (2014) · Journal of Visualized Experiments · doi:10.3791/52065-v · Cited by 159
Schneider, M., Ackermann, K., Stuart, M. A., Wex, C. M., Protzer, U., Schätzl, H. M., & Gilch, S. (2012) · Journal of Virology · doi:10.1128/jvi.01001-12 · Cited by 144
Coronaviridaeand SARS-associated Coronavirus Strain HSR1
Vicenzi, E., Canducci, F., Pinna, D., Mancini, N., Carletti, S., Lazzarin, A., Bordignon, C., Poli, G., & Clementi, M. (2004) · Emerging infectious diseases · doi:10.3201/eid1003.030683 · Cited by 132
Biosafety: Guidelines for Working with Pathogenic and Infectious Microorganisms
Burnett, L. C., Lunn, G., & Coico, R. (2009) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc01a01s13 · Cited by 122
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
Berry, J. D., Jones, S. J. M., DREBOT, M. A., Andonov, A. P., Sabara, M. I. J., Yuan, X. Y., Weingartl, H. M., Fernando, L., Marszal, P., Gren, J., et al. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.04.009 · Cited by 111
Self-citationAssessment of plaque assay methods for alphaviruses
Juárez, D., Long, K. C., Aguilar, P., et al. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.09.026 · Cited by 81
Basic Techniques in Mammalian Cell Tissue Culture
Phelan, K., & May, K. M. (2016) · Current Protocols in Toxicology · doi:10.1002/cptx.13 · Cited by 74
Wang, S., Sakhatskyy, P. V., Chou, T.-H. W., & Lu, S. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.03.008 · Cited by 30
Cited by
Bégin, P., Callum, J., Jamula, E., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01488-2 · Cited by 258
Self-citationHall, V. G., Ferreira, V. H., Wood, H., Ierullo, M., Majchrzak-Kita, B., Manguiat, K., Robinson, A., Kulasingam, V., Humar, A., & Kumar, D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01126-6 · Cited by 114
Self-citationAbe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., et al. (2021) · doi:10.1101/2021.08.06.21261721 · Cited by 32
Self-citationAttenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2023) · doi:10.1101/2023.07.14.549041 · Cited by 1
Metadata
- Authors
- Mendoza, E. J., Manguiat, K., Wood, H., & Drebot, M.
- Venue
- Current Protocols in Microbiology
- Publisher
- Wiley
- Published
- 2020-05-31
- Volume
- 57
- Issue
- 1
- Pages
- ecpmc105-ecpmc105
- ISSN
- 1934-8525 (ISSN-L)
- 1934-8533
- OpenAlex
- W3031193514
- Cited by
- 261
- References
- 22
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.